HC Wainwright Reaffirms “Buy” Rating for Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $40.00 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 403.78% from the stock’s current price.

CAPR has been the subject of several other reports. Oppenheimer restated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday. Finally, Maxim Group reiterated a “buy” rating and issued a $12.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $20.00.

Capricor Therapeutics Stock Up 33.0 %

CAPR traded up $1.97 during midday trading on Tuesday, reaching $7.94. 11,267,752 shares of the company’s stock were exchanged, compared to its average volume of 414,013. The firm has a market capitalization of $253.91 million, a price-to-earnings ratio of -9.09 and a beta of 3.92. The business has a 50-day simple moving average of $4.39 and a two-hundred day simple moving average of $5.19. Capricor Therapeutics has a one year low of $2.68 and a one year high of $9.24.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. As a group, research analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CAPR. BNP Paribas Financial Markets purchased a new stake in Capricor Therapeutics in the first quarter valued at approximately $40,000. Main Street Financial Solutions LLC raised its position in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the last quarter. Rhumbline Advisers purchased a new position in Capricor Therapeutics in the 2nd quarter worth about $147,000. Finally, Renaissance Technologies LLC grew its stake in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.